培米替尼治疗胆管癌相关的视网膜下液：病例报告及文献综述
SUBRETINAL FLUID ASSOCIATED WITH PEMIGATINIB THERAPY FOR CHOLANGIOCARCINOMA: A CASE REPORT AND LITERATURE REVIEW.
作者信息
Caranfa Jonathan T, Mellen Phoebe, Liang Michelle C
机构信息
Retina Department, New England Eye Center, Tufts Medical Center, Boston, Massachusetts.
Retina Vitreous Consultants, Pittsburg, Pennsylvania.
出版信息
Retin Cases Brief Rep. 2024 Nov 1;18(6):722-724. doi: 10.1097/ICB.0000000000001468.
PURPOSE
To describe the retinal findings associated with pemigatinib, an oral competitive inhibitor of fibroblast growth factor receptor approved for the treatment of cholangiocarcinoma.
METHODS
A case report is presented, and a literature review was performed, revealing only two prior reported cases of pemigatinib-mediated subretinal fluid.
RESULTS
A 72-year-old woman presented with transient visual symptoms while on pemigatinib for the treatment of cholangiocarcinoma. Optical coherence tomography revealed subfoveal subretinal fluid bilaterally that resolved during a drug holiday; however, it fluctuated throughout her treatment course. She remained on pemigatinib for 10 months without other ocular sequelae.
CONCLUSION
This is one of the few reported cases of pemigatinib-related retinopathy, which further supports the self-limited and benign nature of subretinal fluid associated with fibroblast growth factor receptor inhibitors.
目的
描述与培米替尼相关的视网膜表现，培米替尼是一种口服成纤维细胞生长因子受体竞争性抑制剂，已被批准用于治疗胆管癌。
方法
报告一例病例，并进行文献综述，发现此前仅报道过两例培米替尼介导的视网膜下液病例。
结果
一名72岁女性在接受培米替尼治疗胆管癌期间出现短暂视觉症状。光学相干断层扫描显示双侧黄斑下视网膜下液在停药期间消退；然而，在整个治疗过程中其有波动。她继续服用培米替尼10个月，未出现其他眼部后遗症。
结论
这是少数几例报道的培米替尼相关性视网膜病变病例之一，进一步支持了与成纤维细胞生长因子受体抑制剂相关的视网膜下液具有自限性和良性的性质。
Zotero 插件